Premium
Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
Author(s) -
Otsuka Fumio,
Takahashi Yutaka,
Tahara Shigeyuki,
Ogawa Yoshihisa,
Højby Rasmussen Michael,
Takano Koji
Publication year - 2020
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.14273
Subject(s) - medicine , adverse effect , endocrinology , clinical endpoint , growth hormone deficiency , randomized controlled trial , growth hormone treatment , adipose tissue , growth hormone , hormone
Somapacitan is a long-acting, reversible albumin-binding growth hormone (GH) derivative in development. This study aimed to evaluate the safety and efficacy of once-weekly somapacitan versus daily GH over 52 weeks in Japanese patients with adult growth hormone deficiency (AGHD).